WASHINGTON — It’s a small update to a Food and Drug Administration policy first launched by the Obama administration, but top Trump health officials — and key congressional Republicans and drug makers — are nonetheless touting it as a central part of the Trump camp’s efforts to lower prescription drug prices.

On Tuesday, the FDA finalized guidance documents, released in draft form in mid-January 2017, making it clear that drug and device companies are allowed to share with insurers information that is not in the FDA-approved labeling. Insurers can use that information to determine how much they should pay for the drugs, FDA commissioner Scott Gottlieb said in a statement.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy